Financial Performance - Revenue for the six months ended June 30, 2024, was RMB 393,093,000, a decrease of 0.4% compared to RMB 395,636,000 for the same period in 2023[2] - Gross profit increased to RMB 315,079,000, representing a 18.4% increase from RMB 266,027,000 year-on-year[2] - Operating profit rose to RMB 127,806,000, up 19.4% from RMB 107,137,000 in the previous year[2] - Profit attributable to shareholders was RMB 104,282,000, a significant increase of 29.0% compared to RMB 80,848,000 in 2023[2] - Basic earnings per share increased to 18.61 cents, up from 14.43 cents in the same period last year[2] - The total revenue for the six months ended June 30, 2024, was RMB 423,209,000, representing an increase of 3% from RMB 410,726,000 in the same period of 2023[9] - Pharmaceutical sales decreased slightly to RMB 393,093,000 from RMB 395,636,000, indicating a decline of approximately 0.6% year-over-year[9] - Other income significantly increased to RMB 30,116,000, up from RMB 15,090,000, marking a growth of 99.5%[9] - Operating profit for the period was impacted by depreciation costs of RMB 10,902,000, down from RMB 32,675,000 in the previous year, reflecting a decrease of 66.6%[9] - The income tax expense for the six months was RMB 22,711,000, a decrease from RMB 24,500,000, which is a reduction of 7.3%[10] - Basic earnings per share increased to RMB 104,282,000, compared to RMB 80,848,000 in the same period last year, representing a growth of 29.0%[10] Assets and Liabilities - Total non-current assets amounted to RMB 1,202,021,000, an increase from RMB 1,117,683,000 as of December 31, 2023[4] - Current assets totaled RMB 1,162,802,000, a decrease from RMB 1,201,141,000 at the end of 2023[5] - Total liabilities decreased to RMB 666,941,000 from RMB 725,289,000 at the end of 2023[5] - Net assets increased to RMB 1,584,662,000, compared to RMB 1,480,380,000 at the end of 2023[5] - Inventory as of June 30, 2024, was valued at RMB 82,356,000, down from RMB 102,972,000, indicating a decrease of 20.0%[13] - The carrying value of property, plant, and equipment decreased to RMB 251,904,000 from RMB 261,559,000, reflecting a decline of 3.7%[11] - The company maintained a cash and bank balance of approximately RMB 342,221,000 as of June 30, 2024, with a net asset value of approximately RMB 1,584,662,000[21] - As of June 30, 2024, the company had short-term bank borrowings of RMB 80,000,000, resulting in a debt-to-equity ratio of approximately 5.05%[22] - The company’s trade receivables as of June 30, 2024, amounted to RMB 273,590,000, compared to RMB 268,327,000 as of December 31, 2023[14] Shareholder Information - As of June 30, 2024, Mr. Zhang Hong holds 101,937,000 shares, representing 26.29% of domestic shares and 18.19% of total registered capital[25] - The major shareholder, Huinan County Caiyuan Investment Co., Ltd., holds 81,975,000 shares, accounting for 21.14% of domestic shares and 14.63% of total registered capital[27] Corporate Governance - The audit committee consists of three independent non-executive directors, responsible for overseeing financial procedures and internal control systems[31] - The company has adopted a code of conduct for securities trading that meets or exceeds the standards set by GEM listing rules[29] - The board of directors has not fully complied with the corporate governance code regarding the separation of the roles of chairman and CEO[30] - There are no known interests held by directors or major shareholders in businesses that may compete with the group[28] Operational Developments - The company expanded its production capacity with the commissioning of new facilities for small-volume injections and added new extraction equipment for traditional Chinese medicine[20] - The company successfully registered several products, including Eberprostat tablets and Dexamethasone sodium phosphate injection, which have entered commercial production[20] - The company is committed to developing potential business opportunities to drive growth and achieve better results in the future[25] - The company employed 678 staff as of June 30, 2024, down from 928 staff a year earlier[32] - The company did not repurchase, sell, or redeem any of its listed shares during the six-month period ending June 30, 2024[33]
吉林长龙药业(08049) - 2024 - 中期财报